Links are not yet activated.
To activate, add a link back to submitpr.org from your website and contact @jaycosta on Telegram,
or pay via Solana (from $19.95) for instant activation.
DENVER, Colo., Sept. 18, 2026 — PlacidWay, a global medical tourism platform, has released new industry research examining how the rapid adoption of GLP-1 medications is influencing international healthcare travel patterns, including changing demand for bariatric surgery and increased interest in post-weight-loss aesthetic procedures. The analysis identifies a shift in the traditional medical tourism pathway, as some patients who previously considered traveling abroad for weight-loss surgery are now exploring medication-based weight management options. At the same time, patients who experience significant weight reduction are increasingly seeking information about procedures designed to address physical changes following weight loss, including body contouring and facial rejuvenation.
Recent healthcare research has documented changing patterns in obesity treatment. A Harvard-affiliated study found that GLP-1 receptor agonist use increased significantly between 2022 and 2024 while metabolic bariatric surger